Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 1. Spectral library from an mIHC assay. Individual examples of ER (fluorescein), PR (A594), Her2 (Cy5), ki67 (Cy3), CK (coumarin), and DAPI, as well as autofluorescence from an unstained section, were spectrally analyzed to generate a spectral library in support of multispectral unmixing in a multiplexed assay. For each epicube in the system, the spectra observed are captured, so that across all epicubes, the complete spectral properties of each independent signal can be effectively utilized for spectral unmixing.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques:

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 2. Automated tissue segmentation. Fluorescent multiplexed IHC (Panel A, see Section 5) of breast tissue stained with ER (green), PR (purple), Her2 (red) and Ki-67 (yellow) is used to train InForm image analysis for tissue segmentation (Panel B). Once segmentation is verified (Panel C), a spectral composite of the multiplexed IHC array is created (Panel D), based on the multispectral unmixed spectra for each fluorescent probe. Bar in A – 100 lm.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Staining

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 3. Simulated IHC images. Fluorescent multiplexed IHC, examining the expression of ER (green), PR (purple), Her2 (red) and Ki-67 (yellow) in breast cancer (Panel A, see Section 5), was spectrally unmixed using InForm. Subsequent simulated H&E (Panel B) and simulated hematoxylin and DAB indicating Her2 expression (Panel C) images were generated to create classic pathology views. Bar in C = 50 lm.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Expressing, Generated

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 5. Analysis of ER expression in multiplex and singleplex contexts. To assess expression of ER within a multiplexed context (ER, PR, Her2, and Ki67 combined spectral composite, panel A), ER was isolated for fluorescent intensity (FU) measurement (spectral composite of ER from multiplex, panel B). ER intensity was also assessed in a sister serial section as a singleplex (panel C). Analyses of average ER fluorescent intensities for all cases (N = 31) between single and multiplexed contexts demonstrated a highly significant correlation (R2 = 0.8320, Pearson r = 0.9122, p < 0.0001, panel D). Bar in C = 100 lm.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Expressing, Multiplex Assay, Isolation

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 6. Analysis of PR expression in multiplex and singleplex contexts. To assess expression of PR within a multiplexed context (ER, PR, Her2, and Ki67 combined spectral composite, panel A), PR was isolated for fluorescent intensity (FU) measurement (spectral composite of PR from multiplex, panel B). PR intensity was also assessed in a sister serial section as a singleplex (panel C). Analyses of average PR fluorescent intensities for all cases (N = 33) between single and multiplexed contexts demonstrated a significant correlation (R2 = 0.6211, Pearson r = 0.7881, p < 0.0001, panel D). Bar in C = 100 lm.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Expressing, Multiplex Assay, Isolation

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 7. Analysis of Her2 expression in multiplex and singleplex contexts. To assess Her2 expression within a multiplexed context (ER, PR, Her2, and Ki67 combined spectral composite, panel A), Her2 was isolated for fluorescent intensity (FU) measurement (spectral composite of Her2 from multiplex, panel B). Her2 fluorescent intensity was also assessed in a sister serial section as a singleplex (panel C). Analyses of average Her2 intensities for all cases (N = 34) between single and multiplexed contexts demonstrated a highly significant correlation (R2 = 0.9884, Pearson r = 0.9942, p < 0.0001, panel D). Bar in C = 100 lm.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Expressing, Multiplex Assay, Isolation

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 8. Analysis of Ki67 expression in multiplex and singleplex contexts. To assess Ki67 expression within a multiplexed context (ER, PR, Her2, and Ki67 combined spectral composite, panel A), Ki67 was isolated for fluorescent intensity (FU) measurement (spectral composite of Ki67 from multiplex, panel B). Ki67 intensity was also assessed in a sister serial section as a singleplex (panel C). Analyses of average Ki67 fluorescent intensities for all cases (N = 30) between single and multiplexed contexts demonstrated a highly significant correlation (R2 = 0.7720, Pearson r = 0.8786, p < 0.0001, panel D). Bar in C = 100 lm.

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Expressing, Multiplex Assay, Isolation

Journal: Methods (San Diego, Calif.)

Article Title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

doi: 10.1016/j.ymeth.2014.08.016

Figure Lengend Snippet: Fig. 9. Analysis of ER, PR, Her2 and Ki67 expression between multiplexed assays in series. To assess the levels of target expression between each breast cancer TMA multiplexed assay, correlational analyses were performed. For ER, analysis of mean fluorescent intensity (FU) between TMA1 and TMA2 stained in series revealed a highly significant correlation (R2 = 0.9451, Pearson r = 0.9722, p < 0.0001, panel A). Assessment of PR intensity between each multiplexed section also revealed a highly significant correlation (R2 = 0.9149, Pearson r = 0.9565, p < 0.0001, panel B). Analysis of Her2 expression between each multiplexed assay resulted in a highly significant correlation (R2 = 0.9852, Pearson r = 0.9926, p < 0.0001, panel C), while Ki67 also exhibited a highly significant correlation (R2 = 0.9639, Pearson r = 0.9679, p < 0.0001, panel D).

Article Snippet: The slides were incubated in antibody diluent for 10 min. Primary antibodies for ER (Abcam SP1, 1:2000), PR (Cell Signaling D8Q2J, 1:2000), Her2 (Cell Signaling 29D8, 1:1000), Ki67 (Dako Mib-1, 1:3000) or cytokeratin (CK; Dako AE1/AE3, 1:2000) were then incubated for 1 h in a humidified chamber at room temperature.

Techniques: Expressing, Staining

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: Sequences used in this study.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques:

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: The expression of lncRNA BMPR1B-AS1 in endometrial cancer tissues and cell lines. A, Volcano map of dysregulated lncRNAs between EC tissues and adjacent normal tissues. The results were obtained from TCGA database. B, Expression levels of lncRNA BMPR1B-AS1 in paired EC and adjacent noncancerous tissues (n = 28). C, RT-qPCR analysis of BMPR1B-AS1 expression in human EC cell lines (Ishikawa, Hec-1a and Hec-1b cells). The data are representative of three independent experiments. Bars, ±SD. **p < 0.01, ****p < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Expressing, Quantitative RT-PCR

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: Overexpression of BMPR1B-AS1 promotes the proliferation, migration and invasion of Hec-1b cells while inhibiting apoptosis. A, Overexpression of BMPR1B-AS1 was confirmed by RT-qPCR. B, Overexpression of BMPR1B-AS1 promoted the proliferation of Hec-1b cells. C, E, G, H, Transwell migration assay (magnification, 200×) and wound healing assay (magnification, 100×) showed that overexpression of BMPR1B-AS1 facilitated the migration of Hec-1b cells. D, F, Transwell invasion assay showed that overexpression of BMPR1B-AS1 facilitated the invasion of Hec-1b cells (magnification, 200×). I, K, Flow cytometry results showed that BMPR1B-AS1 overexpression inhibited Hec-1b cell apoptosis. J, L, Flow cytometry results showed that BMPR1B-AS1 overexpression increased the accumulation of cells in the S-phase and decreased the accumulation of cells in the G0/G1 phase. M, N, O, P, Q, Western blot and analysis showed that the protein level of E-cadherin was decreased, but the protein levels of N-cadherin, Cyclin D1 and CDK4 were increased in the BMPR1B-AS1 overexpression group. Lv, lentiviral vector. The data are representative of three independent experiments. Bars, ±SD. *P < .05, **P < .01, ***P < .001, ****P < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Over Expression, Migration, Quantitative RT-PCR, Transwell Migration Assay, Wound Healing Assay, Transwell Invasion Assay, Flow Cytometry, Western Blot, Plasmid Preparation

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: Knockdown of BMPR1B-AS1 expression inhibits the proliferation, migration and invasion of Ishikawa cells while promoting apoptosis. A, BMPR1B-AS1 knockdown efficiency was confirmed by RT-qPCR. B, Knockdown of BMPR1B-AS1 expression inhibited the proliferation of Ishikawa cells. C, E, G, H, Transwell migration assay (magnification, 200×) and wound healing assay (magnification, 100×) showed that knockdown of BMPR1B-AS1 expression decreased the migration of Ishikawa cells. D, F, Transwell invasion assay showed that knockdown of BMPR1B-AS1 expression decreased the invasion of Ishikawa cells (magnification, 200×). I, K, Flow cytometry results showed that BMPR1B-AS1 knockdown facilitated Ishikawa cell apoptosis. J, L, Flow cytometry results showed that BMPR1B-AS1 knockdown increased the accumulation of cells in the G0/G1 phase and decreased the accumulation of cells in the S-phase. M, N, O, P, Q, Western blot and analysis showed that the protein level of E-cadherin was increased, but the protein levels of N-cadherin, Cyclin D1 and CDK4 were decreased in the BMPR1B-AS1 knockdown group. Sh, short hairpin. The data are representative of three independent experiments. Bars, ±SD. **P < .01, ***P < .001, ****P < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Expressing, Migration, Quantitative RT-PCR, Transwell Migration Assay, Wound Healing Assay, Transwell Invasion Assay, Flow Cytometry, Western Blot

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: BMPR1B-AS1 functions as an efficient miR-7-2-3p sponge in Hec-1b and Ishikawa cells. A, FISH assay showed that the intracellular localization of BMPR1B-AS1 was mainly in the cytoplasm in Ishikawa cells. 18S and U6 were used as controls. B, Putative binding sites of miR-7-2-3p and BMPR1B-AS1. C, Negative correlation was found between BMPR1B-AS1 expression and miR-7-2-3p expression among the 28 endometrial cancer tissue specimens. R = −.549, P = .002. D, E, The effect of the miR-7-2-3p mimic on the luciferase activities of 293 T cells transfected with WT or MUT BMPR1B-AS1 was detected 24 h and 48 h after transfection, respectively. F, RT-qPCR results showed that miR-7-2-3p expression was downregulated after BMPR1B-AS1 overexpression in Hec-1b cells. G, RT-qPCR results showed that miR-7-2-3p expression was upregulated after BMPR1B-AS1 knockdown in Ishikawa cells. H, miR-7-2-3p expression was upregulated after transfection with the miR-7-2-3p mimic in Hec-1b cells. I, The miR-7-2-3p mimic reversed the BMPR1B-AS1-mediated downregulation of miR-7-2-3p expression. J, miR-7-2-3p expression was downregulated after transfection of Ishikawa cells with the miR-7-2-3p inhibitor. K, The miR-7-2-3p inhibitor attenuated the BMPR1B-AS1-mediated upregulation of miR-7-2-3p expression. The data are representative of three independent experiments. Bars, ±SD. *P < .05, **P < .01, ***P < .001, ****P < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Binding Assay, Expressing, Luciferase, Transfection, Quantitative RT-PCR, Over Expression

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: Upregulation of miR-7-2-3p expression reverses the BMPR1B-AS1 overexpression-induced progression of Hec-1b cells. A, CCK8 assay showed that cotransfection with the miR-7-2-3p mimic suppressed the BMPR1B-AS1 overexpression-induced proliferation of Hec-1b cells. B, D, F, G, Transwell migration assay (magnification, 200×) and wound healing assay (magnification, 100×) showed that cotransfection with the miR-7-2-3p mimic suppressed the BMPR1B-AS1 overexpression-induced migration of Hec-1b cells. C, E, Transwell invasion assay (magnification, 200×) showed that cotransfection with the miR-7-2-3p mimic suppressed the BMPR1B-AS1 overexpression-induced invasion of Hec-1b cells. H-K, Flow cytometry showed that cotransfection with the miR-7-2-3p mimic accelerated apoptosis and cell cycle arrest, and these effects were inhibited by BMPR1B-AS1 overexpression in Hec-1b cells. The data are representative of three independent experiments. Bars, ±SD. *P < .05, **P < .01, ***P < .001, ****P < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Expressing, Over Expression, CCK-8 Assay, Cotransfection, Transwell Migration Assay, Wound Healing Assay, Migration, Transwell Invasion Assay, Flow Cytometry

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: Downregulation of miR-7-2-3p expression reverses the BMPR1B-AS1 knockdown-mediated inhibition of Ishikawa cells. A, CCK8 assay showed that cotransfection with the miR-7-2-3p inhibitor reversed the BMPR1B-AS1 knockdown-mediated inhibition of proliferation of Ishikawa cells. B, D, F, G, Transwell migration assay (magnification, 200×) and wound healing assay (magnification, 100×) showed that cotransfection with the miR-7-2-3p inhibitor reversed the BMPR1B-AS1 knockdown-mediated inhibition of migration of Ishikawa cells. C, E, Transwell invasion assay (magnification, 200×) showed that cotransfection with the miR-7-2-3p inhibitor reversed the BMPR1B-AS1 knockdown-mediated inhibition of invasion of Ishikawa cells. H-K, Flow cytometry showed that cotransfection with the miR-7-2-3p inhibitor inhibited apoptosis and cell cycle arrest, and these effects were enhanced by BMPR1B-AS1 knockdown in Ishikawa cells. The data are representative of three independent experiments. Bars, ±SD. **P < .01, ***P < .001, ****P < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Expressing, Inhibition, CCK-8 Assay, Cotransfection, Transwell Migration Assay, Wound Healing Assay, Migration, Transwell Invasion Assay, Flow Cytometry

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: DCLK1 is a target gene of miR-7-2-3p, and BMPR1B-AS1 regulates DCLK1 expression by competitively binding to miR-7-2-3p in EC cell lines. A, Putative binding sites of miR-7-2-3p and DCLK1 mRNA. B, C, The effect of the miR-7-2-3p mimic on the luciferase activities of cells transfected with WT or MUT DCLK1 was detected after 24 h and 48 h, respectively. D, Negative correlation was found between miR-7-2-3p expression and DCLK1 mRNA expression among the 28 endometrial cancer tissue specimens. R = −.531, P = .004. E, Positive correlation was found between BMPR1B-AS1 expression and DCLK1 mRNA expression among the 28 endometrial cancer tissue specimens. R = .690, P = .000. F, J, N, RT-qPCR and western blotting results showed that DCLK1 mRNA and protein expression was upregulated after BMPR1B-AS1 overexpression. G, K, O, RT-qPCR and western blotting results showed that DCLK1 mRNA and protein expression was downregulated after BMPR1B-AS1 knockdown. H, L, P, RT-qPCR and western blotting results showed that the miR-7-2-3p mimic attenuated the BMPR1B-AS1-mediated upregulation of DCLK1 mRNA and protein expression. I, M, Q, RT-qPCR and western blotting results showed that the miR-7-2-3p inhibitor reversed the effects of BMPR1B-AS1 knockdown on DCLK1 mRNA and protein expression. The data are representative of three independent experiments. Bars, ±SD. *P < .05, **P < .01, ***P < .001, ****P < 0.0001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: Expressing, Binding Assay, Luciferase, Transfection, Quantitative RT-PCR, Western Blot, Over Expression

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: BMPR1B-AS1 promotes endometrial cancer cell growth in vivo by targeting miR-7-2-3p. A, Images of tumor xenografts. B, The growth curves of tumor xenografts demonstrated that BMPR1B-AS1 significantly promote tumor growth in vivo , which was reversed by treatment with agomir-7-2-3p. **P < 0.01 vs. Lv-BMPR1B-AS1, ***P < 0.001 vs. Lv-BMPR1B-AS1, ****P < 0.0001 vs. Lv-BMPR1B-AS1, # P < 0.05 vs. Lv-BMPR1B-AS1+ agomiR-7-2-3p. C, The weights of tumor xenografts derived from five groups. D, The expression levels of BMPR1B-AS1 in five groups were examined by RT-qPCR. E, The expression levels of miR-7-2-3p in five groups were examined by RT-qPCR. F, G, The expression levels of DCLK1 in five groups were examined by RT-qPCR and IHC. H, Negative correlation was found between BMPR1B-AS1 and miR-7-2-3p expression in xenografts tissues. R = −.506, P = .000. I, Negative correlation was found between miR-7-2-3p and DCLK1 mRNA expression in xenografts tissues. R = −.452, P = .001. J. Positive correlation was found between BMPR1B-AS1 and DCLK1 mRNA expression in xenografts tissues. R = .387, P = .006. *P < .05, **P < .01, ***P < .001.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: In Vivo, Derivative Assay, Expressing, Quantitative RT-PCR

Journal: Cell Cycle

Article Title: Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway

doi: 10.1080/15384101.2022.2060003

Figure Lengend Snippet: A schematic model of the mechanism by which lncRNA BMPR1B-AS1 regulates endometrial cancer cell malignant behaviors. The BMPR1B-AS1/miR-7-2-3p/DCLK1 axis promotes the progression of endometrial cancer cells via the PI3K/Akt/NF-κB signaling pathway.

Article Snippet: Digoxigenin (DIG)-labeled BMPR1B-AS1 probes were designed and synthesized by BOSTER (Wuhan, China).

Techniques: